查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1699327

動物藥物市場機會、成長動力、產業趨勢分析及 2025-2034 年預測

Animal Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 155 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球動物藥物市場規模達 433 億美元，預計 2025 年至 2034 年複合年成長率為 6.1%。市場成長的動力包括寵物擁有增加、牲畜醫療保健需求增加以及獸醫學的進步。隨著越來越多的人將寵物視為伴侶，對用於治療各種健康問題的高品質藥品的需求也在激增。

動物藥市場 - IMG1

同樣，畜牧業也越來越重視疾病預防和生產力提高，從而刺激了對專用藥物的需求。關節炎、糖尿病和心血管疾病等動物慢性疾病的發生率不斷上升，導致獸醫支出增加，促使人們開發更有效的治療方案。預防保健意識的不斷增強，加上創新獸藥的監管批准，進一步加速了市場的成長。隨著研發工作的不斷開展和獸醫護理服務可及性的提高，該行業有望繼續擴張。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 433億美元
預測值 789億美元
複合年成長率 6.1%

藥品創新與分銷網路的改善使得動物藥品在各個地區更容易取得。政府和私人組織正在積極支持獸醫研究，從而引入旨在最大限度縮短恢復時間和增強動物整體健康的先進治療方法。此外，寵物保險覆蓋率的激增也鼓勵寵物主人投資高品質的藥物，確保更好地遵守治療法規。

2024 年，藥品領域以 238 億美元的規模佔據市場主導地位，這得益於其在治療感染、發炎和寄生蟲感染方面的重要作用。獸藥的配方擴大用於提供有針對性的治療，減少副作用並提高療效。人畜共通傳染病發生率的上升也增加了對先進藥物的需求，促使製藥公司投資於尖端研究。寵物主人越來越積極關注寵物的健康，選擇能夠更快恢復並帶來長期益處的處方藥。人們對抗生素抗藥性的日益擔憂推動了益生菌和免疫調節劑等替代療法的採用，進一步使藥物模式多樣化。

2024 年，伴侶動物佔了 59.2% 的市場佔有率，反映出越來越多的家庭收養寵物並重視寵物的醫療保健。可支配收入的增加，加上對寵物的情感依戀，導致獸醫支出增加，特別是在專門藥物方面的支出。隨著寵物主人尋求延長寵物的壽命並提高其生活品質，對疫苗和營養補充劑等預防性治療的需求正在激增。獸醫診斷技術的進步也在該領域的發展中發揮關鍵作用，實現了早期疾病檢測和個人化治療方法。

2024 年，北美佔據了 41.4% 的市場佔有率，由於寵物擁有率高和獸醫醫療保健體系完善，保持了主導地位。該地區重要的畜牧業繼續推動對旨在改善畜群健康和生產力的藥品的需求。不斷擴大的研究計劃，加上對創新獸醫治療日益加強的監管支持，正在促進產業成長。生物製劑和基因療法等先進治療方案的日益普及正在塑造動物保健的未來，確保整個地區對藥品的持續需求。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
  • 產業衝擊力
    • 成長動力
      • 動物疾病發生率上升
      • 日益關注畜牧業生產力
      • 寵物保險需求激增
      • 政府對動物福利的計劃和支持日益增多
      • 加強研發活動推廣獸醫學進步
      • 擴大網路獸醫藥房
    • 產業陷阱與挑戰
      • 不良副作用和藥品召回
      • 動物藥物研發成本高
  • 成長潛力分析
  • 監管格局
    • 北美洲
    • 歐洲
    • 亞太地區
  • 政策格局
  • 產品線分析
  • 投資者概覽
  • 差距分析
  • 消費者行為趨勢
  • 波特的分析
  • PESTEL分析

第4章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 策略儀表板

第5章：市場估計與預測：按產品，2021 年至 2034 年

  • 主要趨勢
  • 藥物
    • 抗寄生蟲藥
    • 消炎劑
    • 抗感染藥物
    • 皮質類固醇
    • 鎮靜劑
    • 心血管藥物
    • 胃腸道藥物
  • 疫苗
    • 減毒活疫苗（MLV）
    • 去活化疫苗
    • 重組疫苗
  • 藥物飼料添加劑
    • 抗生素
    • 維生素
    • 胺基酸
    • 酵素
    • 抗氧化劑
    • 益生元和益生菌
    • 礦物質
    • 其他藥物飼料添加劑

第6章：市場估計與預測：依動物類型，2021 年至 2034 年

  • 主要趨勢
  • 伴侶動物
    • 狗
    • 貓
    • 馬匹
    • 其他伴侶動物
  • 家畜
    • 家禽
    • 豬
    • 牛
    • 魚
    • 其他牲畜

第7章：市場估計與預測：依管理路線，2021 年至 2034 年

  • 主要趨勢
  • 口服
  • 注射劑
  • 外用
  • 其他給藥途徑

第8章：市場估計與預測：按配銷通路，2021 年至 2034 年

  • 主要趨勢
  • 獸醫院藥房
  • 電子商務
  • 零售藥局

第9章：市場估計與預測：按地區，2021 年至 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 波蘭
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 台灣
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 海灣合作理事會國家
    • 以色列

第10章：公司簡介

  • Agrolabo
  • Boehringer Ingelheim International
  • Ceva Santé Animale
  • Chanelle Pharma
  • Dechra Pharmaceuticals
  • Durvet
  • Elanco Animal Health
  • Endovac Animal Health
  • HIPRA
  • Indian Immunologicals
  • Merck
  • Norbrook
  • Neogen Corporation
  • Symrise
  • Vetoquinol
  • Virbac
  • Zoetis
簡介目錄
Product Code: 4445

The Global Animal Drugs Market reached USD 43.3 billion in 2024 and is projected to register a CAGR of 6.1% from 2025 to 2034. The market growth is driven by a combination of rising pet ownership, increasing demand for livestock healthcare, and advancements in veterinary medicine. As more people embrace pets as companions, the need for high-quality pharmaceuticals to address a wide range of health conditions is surging.

Animal Drugs Market - IMG1

Likewise, the livestock industry is witnessing a growing emphasis on disease prevention and productivity enhancement, fueling demand for specialized drugs. The rising prevalence of chronic diseases in animals, including arthritis, diabetes, and cardiovascular disorders, is pushing veterinary expenditures higher, prompting the development of more effective treatment options. Increasing awareness about preventive care, coupled with regulatory approvals for innovative veterinary pharmaceuticals, is further accelerating market growth. With ongoing R&D efforts and improved accessibility to veterinary care, the industry is poised for continued expansion.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$43.3 Billion
Forecast Value$78.9 Billion
CAGR6.1%

Pharmaceutical innovations, in line with improved distribution networks, are making animal drugs more accessible across regions. Governments and private organizations are actively supporting veterinary research, leading to the introduction of advanced therapeutics designed to minimize recovery time and enhance overall animal well-being. Additionally, a surge in pet insurance coverage is encouraging pet owners to invest in high-quality medications, ensuring better treatment adherence.

The drugs segment led the market in 2024 with USD 23.8 billion, dominating due to its essential role in treating infections, inflammation, and parasitic infestations. Veterinary pharmaceuticals are increasingly being formulated to provide targeted treatment, reducing side effects and improving efficacy. The rising incidence of zoonotic diseases is also reinforcing the demand for advanced medications, prompting pharmaceutical companies to invest in cutting-edge research. Pet owners are becoming more proactive about their animals' health, opting for prescription medications that offer faster recovery and long-term benefits. Growing concerns over antimicrobial resistance are driving the adoption of alternative treatments, including probiotics and immunomodulators, further diversifying the drug landscape.

Companion animals accounted for 59.2% of the market share in 2024, reflecting the increasing number of households adopting pets and prioritizing their medical care. Rising disposable income, coupled with an emotional attachment to pets, is leading to higher veterinary spending, particularly on specialized medications. The demand for preventative treatments, including vaccines and nutritional supplements, is surging as pet owners seek to enhance their animals' longevity and quality of life. Technological advancements in veterinary diagnostics are also playing a key role in the segment's growth, enabling early disease detection and personalized treatment approaches.

North America accounted for 41.4% of the market share in 2024, maintaining its dominance due to high pet ownership rates and a well-established veterinary healthcare system. The region's significant livestock industry continues to drive demand for pharmaceuticals aimed at improving herd health and productivity. Expanding research initiatives, combined with growing regulatory support for innovative veterinary treatments, are reinforcing industry growth. The increasing availability of advanced treatment options, such as biologics and gene-based therapies, is shaping the future of animal healthcare, ensuring sustained demand for pharmaceuticals across the region.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of animal diseases
      • 3.2.1.2 Growing focus on livestock productivity
      • 3.2.1.3 Surging demand for pet insurance policies
      • 3.2.1.4 Growing government initiatives and support towards animal welfare
      • 3.2.1.5 Intensified R&D activities drive advancements in veterinary medicine
      • 3.2.1.6 Expanding online veterinary pharmacies
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Adverse side effects and drug recalls
      • 3.2.2.2 High cost associated with animal drugs development
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Policy landscape
  • 3.6 Product pipeline analysis
  • 3.7 Investor overview
  • 3.8 GAP analysis
  • 3.9 Consumer behaviour trends
  • 3.10 Porter's analysis
  • 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Drugs
    • 5.2.1 Antiparasitic
    • 5.2.2 Anti-inflammatory
    • 5.2.3 Anti-infectives
    • 5.2.4 Corticosteroids
    • 5.2.5 Tranquilizers
    • 5.2.6 Cardiovascular drugs
    • 5.2.7 Gastrointestinal drugs
  • 5.3 Vaccines
    • 5.3.1 Modified live vaccines (MLV)
    • 5.3.2 Killed inactivated vaccines
    • 5.3.3 Recombinant vaccines
  • 5.4 Medicated feed additives
    • 5.4.1 Antibiotics
    • 5.4.2 Vitamins
    • 5.4.3 Amino acids
    • 5.4.4 Enzymes
    • 5.4.5 Antioxidants
    • 5.4.6 Prebiotics and probiotics
    • 5.4.7 Minerals
    • 5.4.8 Other medicated feed additives

Chapter 6 Market Estimates and Forecast, By Animal Type, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Companion animals
    • 6.2.1 Dogs
    • 6.2.2 Cats
    • 6.2.3 Horses
    • 6.2.4 Other companion animals
  • 6.3 Livestock animals
    • 6.3.1 Poultry
    • 6.3.2 Swine
    • 6.3.3 Cattle
    • 6.3.4 Fish
    • 6.3.5 Other livestock animals

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Injectable
  • 7.4 Topical
  • 7.5 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Veterinary hospital pharmacies
  • 8.3 E-commerce
  • 8.4 Retail pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Poland
    • 9.3.7 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Taiwan
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 GCC Countries
    • 9.6.3 Israel

Chapter 10 Company Profiles

  • 10.1 Agrolabo
  • 10.2 Boehringer Ingelheim International
  • 10.3 Ceva Santé Animale
  • 10.4 Chanelle Pharma
  • 10.5 Dechra Pharmaceuticals
  • 10.6 Durvet
  • 10.7 Elanco Animal Health
  • 10.8 Endovac Animal Health
  • 10.9 HIPRA
  • 10.10 Indian Immunologicals
  • 10.11 Merck
  • 10.12 Norbrook
  • 10.13 Neogen Corporation
  • 10.14 Symrise
  • 10.15 Vetoquinol
  • 10.16 Virbac
  • 10.17 Zoetis